News | Cardiac Diagnostics

Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis, according to research presented at the annual meeting of the Radiological Society of North America (RSNA), Nov. 26-Dec. 1 in Chicago. The increased risk, which was not evident in female triathletes, was directly associated with the athletes’ amount of exercise.

Home January 09, 2018
Home
News | Advanced Visualization

EchoPixel showcased the latest version of True 3D, its interactive, mixed reality software solution at the 103rd Annual Radiological Society of North America (RSNA) meeting, Nov. 26-Dec. 1, 2017, in Chicago. True 3D was featured in the Virtual Reality Showcase in the RSNA Learning Center.

Home January 08, 2018
Home
News | Robotic Systems

Corindus Vascular Robotics Inc. announced that it is working with Mayo Clinic in a preclinical study about use of telestenting. Telestenting, a remote robotic treatment for percutaneous coronary intervention (PCI), may enable physicians to conduct procedures from virtually any location, opening opportunities for more patients globally to receive the benefits of this lifesaving procedure. The global shortage of PCI-capable operators is significant and continues to be a growing problem.

Home January 08, 2018
Home
News | Stent Grafts

January 8, 2018 — W. L. Gore & Associates Inc. announced the first implant of the Gore Excluder Conformable AAA ...

Home January 08, 2018
Home
News | Interventional Radiology

Guerbet announced that it has entered into an agreement under which it will acquire Israeli company Accurate Medical Therapeutics , which specializes in the development of microcatheters used in interventional radiology.

Home January 08, 2018
Home
Drinking coffee may be associated with a decreased risk of developing heart failure or having stroke, according to preliminary research presented at the 2017 American Heart Association (AHA) Scientific Sessions in November. Researchers used machine learning to analyze data from the long-running Framingham Heart Study, which includes information about what people eat and their cardiovascular health.
Feature | Dave Fornell

Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magazine ...

Home January 08, 2018
Home
News | Cardiovascular Business

January 8, 2018 — Canon Inc. and Canon Medical Systems Corp. announced the official corporate name change of Canon Group ...

Home January 08, 2018
Home
Videos | Cath Lab

Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif., and ...

Home January 04, 2018
Home
News | Cath Lab

The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer Sheath’s hemostatic valve that prevents blood from flowing back through the valve, warning that it may fail due to an improper seal of the sheath hub. The agency said improper seals can allow blood to leak through the hub, cause the cap to fall off during the procedure, or can create a difference in pressure that allows air into the circulatory system (air embolism). The FDA warned the use of affected products may cause serious health consequences for patients, including death.

Home January 04, 2018
Home
Videos | Heart Valve Technology

Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how his ...

Home January 04, 2018
Home
Technology | Cardiac Resynchronization Therapy Devices (CRT)

Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for the Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D) and Fortify Assura implantable cardioverter defibrillator (ICD). The approvals follow recent MR-conditional labeling approvals for the Assurity MRI pacemaker, Ellipse ICD and associated MRI-compatible leads, and further expand Abbott's portfolio of MRI-ready devices for patients indicated for ICDs and/or CRT-D devices who may need an MRI in the future.

Home January 03, 2018
Home
News | Medical 3-D Printing

The U.S. Food and Drug Administration (FDA) issued the final version of the guidance, “Technical Considerations for Additive Manufactured Medical Devices." Additive manufacturing (AM), the broad category of manufacturing encompassing three-dimensional (3-D) printing, is an emerging technology. This guidance is not intended to introduce new policy, but rather outlines the Agency’s current thinking about the technical aspects associated with AM processes, and provides manufacturers with recommendations for device design, manufacturing and testing considerations for use when developing devices that include at least one additively manufactured component or additively fabricated step.

Home January 03, 2018
Home
News | Cardiovascular Ultrasound

Chagas disease (ChD), an infectious parasitic disease transmitted primarily by triatomine insects, has become a significant public health problem in recent decades. While many ChD patients suffer only minor symptoms, 20-30 percent develop chronic heart disease (ChHD); the variety of possible abnormalities caused by ChHD requires understanding of how different imaging modalities can assist in diagnosis and treatment decisions. A new document, Recommendations for Multimodality Cardiac Imaging in Patients with Chagas Disease: A Report from the American Society of Echocardiography in Collaboration With the InterAmerican Association of Echocardiography (ECOSIAC) and the Cardiovascular Imaging Department of the Brazilian Society of Cardiology (DIC-SBC), aims to provide the first comprehensive guidance for how best to use the multiple cardiac diagnostic tools to assess and monitor the growing number of patients with these Chagas-induced heart problems.

Home January 03, 2018
Home
News | Vena Cava Filters

January 2, 2018 — Osborne & Associates Law Firm, P.A., of Boca Raton, Fla., has filed suit in Palm Beach Circuit Court ...

Home January 02, 2018
Home
News | Heart Failure

RenalGuard Solutions Inc. reported positive results from a first-in-man feasibility study focusing on a novel use of the RenalGuard System to manage fluids during diuretic therapy in congestive heart failure patients suffering from fluid overload. The results were recently presented at the annual Devices in Heart Failure (D-HF) Congress, Dec. 15-16 in Berlin, Germany, by Prof. Piotr Ponikowski, M.D., of the Wroclaw Medical University, Poland, and Prof. Felix Mahfoud, M.D., of the Saarland University Hospital, Homburg, Germany.

Home January 02, 2018
Home
Subscribe Now